Furthermore, genetic associations in cancer patients indicate that combining anti‐IL‐1 strategies with checkpoint blockade immunotherapy may benefit patients with haematological, pancreatic or breast cancer, and clinical trials are ongoing.126. This evidence concerns the gene IL1B and cancer.